At the news
? BEARISHIMPACT 8/10 424B5 filed Jul 22, 2026 at 17:13 ET
KALA BIO filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $250,000,000 in common stock through H.C. Wainwright. This massive potential dilution, up to 337.8 million shares at the current $0.78 price, more than 17x the existing 19.3 million shares outstanding, signals severe financial distress for a company with no revenue, no ongoing clinical trials, and a market cap of only $14M. The filing explicitly warns of going concern risk, Nasdaq delisting risk, and the need for additional capital, making this a deeply bearish event for existing shareholders.
- KALA BIO entered into an ATM Sales Agreement with H.C. Wainwright to sell up to $250,000,000 of common stock.
- At the July 17, 2026 closing price of $0.78, this represents up to 337,837,838 shares, which is over 17x the current 19,339,786 shares outstanding.
- The company has no ongoing clinical trials after the CHASE Phase 2b trial failed in September 2025, and is pivoting to an unproven AI platform-as-a-service business.
- The filing explicitly mentions risks related to going concern, Nasdaq delisting (stock recently traded below $1.00), and the need for additional financing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access